UCI Says Its Antibody Treatment Could Reduce COVID-19 Hospitalizations Nationwide


Medical researchers at the University of California–Irvine (UCI) say their ongoing success with administering antibodies to treat COVID-19 could slow hospitalizations nationwide.

The UCI Health researchers say they continue to see positive results in their clinical method for infusing patients with monoclonal antibodies—laboratory-made proteins that mimic the immune system’s ability to fight off viruses—for the second consecutive week.

Dr. Alpesh N. Amin, UCI’s chairman of the department of medicine and the project’s lead investigator, told The Epoch Times on Feb. 16 the project is “a way of helping not only our patient population, but also our community at large” by attempting to verify “whether monoclonal antibodies could be given to patients to help prevent progression of their illness that would lead to hospitalizations or the visits.”

By providing another option for COVID-19 treatment, researchers are hoping it will block the disease from progressing to a hospital-room visit. According to Amin, published preliminary data shows that monoclonal antibodies would reduce both emergency room visits and hospitalizations by up to 70 percent.

Read the rest of the story on The Epoch Times

Get Citizensjournal.us Headlines free  SUBSCRIPTION. Keep us publishing – DONATE

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments